Comparison of cabozantinib with axitinib as second-line treatment for metastatic kidney cancer
To date, there have not been any studies that have [...]
Factors affecting outcomes after nephrectomy for metastatic kidney cancer
Nephrectomy is surgery to remove all or part of a [...]
Adjuvant pembrolizumab prolongs overall survival for kidney cancer patients
Surgery (partial or radical nephrectomy) is the standard of care [...]
Immunotherapy combinations versus TKIs for papillary renal cell carcinoma
Papillary renal cell carcinoma (pRCC) is the most common subtype [...]
CAR T cell immunotherapy shows promise for patients with kidney cancer
Chimeric antigen receptor (CAR) T cell therapy is a type [...]
Real world data on the use of cabozantinib plus immunotherapy in the second line
A recent study looked at the use of a combination [...]
Immunotherapy improves survival in kidney cancer patients with brain metastases
A recent real world study has found that giving immunotherapy [...]
PRISM study highlights possibility of reducing dose of immunotherapy
The CheckMate-214 clinical trial was the first study to show [...]
Summary of kidney cancer highlights from ASCO GU 2024
This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]
Cancer treatment could identify patients most likely to respond to cancer drugs
Scientists from Cancer Research UK and Memorial Sloan Kettering Cancer [...]
